Unmasking the pathogenic role of IL-17 axis in primary Sjögren's syndrome: A new era for therapeutic targeting?

Alunno, Alessia; Carubbi, Francesco; Bartoloni, Elena; Bistoni, Onelia; Caterbi, Sara; Cipriani, Paola; Giacomelli, Roberto; Gerli, Roberto

doi:10.1016/j.autrev.2014.08.022

Cited by 42 publications

(34 citation statements)

References 98 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This observation seems to reinforce the role of IL-17-producing T cells in pSS pathogenesis [33]. The IL-17 axis appears to be crucial in the induction as well as the maintenance of pSS independently of the clinical or serological features of the disease.…”

mentioning

confidence: 51%

Interleukin (IL)-17-producing pathogenic T lymphocytes co-express CD20 and are depleted by rituximab in primary Sjögren's syndrome: a pilot study

Alunno

Carubbi

Bistoni

et al. 2016

Clinical and Experimental Immunology

View full text Add to dashboard Cite

1These authors contributed equally to the study. SummaryCompelling evidence suggests that interleukin (IL)-17 and IL-17-producing cells play a pivotal role in the pathogenesis of primary Sj€ ogren's syndrome (pSS). We investigated phenotypical and functional effects of the anti-CD20 antibody rituximab (RTX) on circulating and glandular IL-17-producing T cells in pSS. RTX is able to deplete glandular IL-

show abstract

mentioning

confidence: 51%

Interleukin (IL)-17-producing pathogenic T lymphocytes co-express CD20 and are depleted by rituximab in primary Sjögren's syndrome: a pilot study

Alunno

Carubbi

Bistoni

et al. 2016

Clinical and Experimental Immunology

View full text Add to dashboard Cite

show abstract

“…Lastly, lacrimal IL-17 is increased in patients with pSS relative to those with dry eye syndrome of other etiologies. Although yet unemployed, it has been suggested that targeting the IL-17/Th17 axis represents a credible therapeutic approach to pSS[28]. …”

Section: Interleukin-17mentioning

confidence: 99%

The role of IL-17 in vitiligo: A review

Singh

Lee

Vujkovic-Cvijin

et al. 2016

Autoimmunity Reviews

115

101

View full text Add to dashboard Cite

IL-17 is involved in the pathogenesis of several autoimmune diseases, however its role in vitiligo has not been well defined. Emerging human and mouse studies have demonstrated that systemic, tissue, and cellular levels of IL-17 are elevated in vitiligo. Many studies have also shown significant positive correlations between these levels and disease activity, extent, and severity. Treatments that improve vitiligo, such as ultraviolet B phototherapy, also modulate IL-17 levels. This review synthesizes our current understanding of how IL-17 may influence the pathogenesis of autoimmune vitiligo at the molecular level. This has implications for defining new vitiligo biomarkers and treatments.

show abstract

“…Overexpression of proinflammatory cytokines, such as interleukin-1, and interleukin-17, and lower expression of anti-inflammatory cytokine, such as interleukin-4 is an important manifestation of immune disorder in SS [18, 19]. Recent advances in the understanding of its pathogenesis have uncovered some pathways that have potential as therapeutic targets.…”

Section: Introductionmentioning

confidence: 99%

Is hydroxychloroquine effective in treating primary Sjogren’s syndrome: a systematic review and meta-analysis

Wang

Zhang

Pan

et al. 2017

BMC Musculoskelet Disord

View full text Add to dashboard Cite

BackgroundTo systematically review and assess the efficacy and safety of hydroxychloroquine (HCQ) for treating primary Sjogren’s syndrome (pSS).MethodsFive electronic databases (Pubmed, EMBASE, Web of science, Ovid, Cochrane Library) were searched for randomized controlled trials and retrospective or prospective studies published in English that reported the effect of HCQ on pSS. The subjective symptoms (sicca symptoms, fatigue and pain) and the objective indexes (erythrocyte sedimentation rate and Schirmer test) were assessed as main outcome measures. A meta-analysis and descriptive study on the efficacy and safety of HCQ were conducted. The estimate of the effect of HCQ treatment was expressed as a proportion together with 95% confidence interval, and plotted on a forest plot.ResultsFour trials with totals of 215 SS patients, including two randomized controlled trials, one double blind crossover trial and one retrospective open-label study, were analyzed in this review. For dry mouth and dry eyes, the effectiveness of HCQ treatment was essentially the same as placebo treatment. For fatigue, the effectiveness of HCQ was lower than placebo. The efficacy of HCQ in treating pain associated with pSS was superior to that of the placebo. There was no significant difference between HCQ-treated groups and controls in terms of Schirmer test results, but HCQ could reduce the erythrocyte sedimentation rate compare with placebo. A descriptive safety assessment showed that gastrointestinal adverse effects were the most common adverse effects associated with HCQ.ConclusionsThis systematic review showed that there is no significant difference between HCQ and placebo in the treatment of dry mouth and dry eye in pSS. Well-designed, randomized, controlled trials are needed to provide higher-quality evidence to confirm our findings, and future studies should focus on some other index or extraglandular measures, such as cutaneous manifestations, to further explore the therapeutic effect of HCQ in pSS.Electronic supplementary materialThe online version of this article (doi:10.1186/s12891-017-1543-z) contains supplementary material, which is available to authorized users.

show abstract

Unmasking the pathogenic role of IL-17 axis in primary Sjögren's syndrome: A new era for therapeutic targeting?

Cited by 42 publications

References 98 publications

Interleukin (IL)-17-producing pathogenic T lymphocytes co-express CD20 and are depleted by rituximab in primary Sjögren's syndrome: a pilot study

Interleukin (IL)-17-producing pathogenic T lymphocytes co-express CD20 and are depleted by rituximab in primary Sjögren's syndrome: a pilot study

The role of IL-17 in vitiligo: A review

Is hydroxychloroquine effective in treating primary Sjogren’s syndrome: a systematic review and meta-analysis

Contact Info

Product

Resources

About